U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07331103) titled 'RESOLving INflammation Through Diet for Health (RESOLVIN)' on Dec. 12, 2025.
Brief Summary: Hyperlipidemia is the main driver of atherosclerotic cardiovascular disease (ASCVD), both through direct effects and as trigger of the chronic inflammation behind a cardiovascular health-to-disease transition. While lipid-lowering is an effective way to reduce the ASCVD risk, the residual risk remains high. In addition, a substantial proportion of ASCVD events occur in the absence of overt hyperlipidemia. Several lines of evidence ranging from experimental models to population studies and interventional clinical trials support chronic inflamm...